Quantcast

Latest Cetuximab Stories

2011-09-07 19:57:00

Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug. Jamming those circuits with targeted therapies may heighten or restore the drug's potency, according to a study published in the Sept. 7 issue of Science Translational Medicine. The research focused on the drug cetuximab, an antibody that interferes with cancer cell growth by blocking a structure...

2011-08-05 02:00:00

GERMANTOWN, Maryland and HILDEN, Germany, August 5, 2011 /PRNewswire/ -- ? - Food and Drug Administration will review therascreen(R) KRAS RGQ PCR Kit for use with Erbitux(R) (cetuximab), a metastatic colorectal cancer therapy - PMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancer - QIAGEN achieves milestones in Personalized Healthcare with...

2011-07-27 07:35:00

QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer. The trial, involving over 430 patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) and with Fast Track Designation. It is sponsored by Keryx Biopharmaceuticals, Inc.,...

2011-07-27 07:30:00

NEW YORK, July 27, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer. This Phase 3 trial, with over 430 randomized patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) and with Fast-Track Designation. Perifosine is a novel, potentially...

2011-06-07 15:20:31

A study of more than 1,000 patients with colon cancer that had spread to distant sites found that one in eight was treated with at least one drug regimen that was not recommended. Those patients were exposed to significant risk without proven benefits, at an estimated cost"”just for the drugs"”of more than $2 million. The study, presented June 7, 2011, by University of Chicago researchers at the American Society for Clinical Oncology's annual meeting in Chicago, focused on three...

2011-05-26 09:14:00

OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's (Bronx, NY, US) patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib". The invention relates to the discovery by Montefiore scientists and collaborators that tumor-specific mutations in the genes PIK3CA and PTEN can aid in...

2011-05-25 11:28:00

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed...

2011-05-11 19:40:21

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that a decoy receptor might be limiting the amount of drug that gets to the intended target. "We know that smart drugs like Cetuximab are not always effective in the cancer cells...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'